Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

This study is evaluating whether the 9-valent HPV (human papillomavirus) vaccine provides the same level of immune protection in younger Chinese females (ages 9–19) compared to older women (ages 20–45). If results show similar immunity, the vaccine could be approved for use in younger age groups in China. **You may be eligible if...** - You are a healthy Chinese female between 9 and 45 years old (for the first stage) or 9–19 years old (for the second stage) - You are willing to participate and, if a minor, your legal guardian also consents - You have a negative pregnancy test on the day of enrollment (if of childbearing age) - You are using effective contraception or are not sexually active - You have received all 3 doses of the trial vaccine (for the second stage) **You may NOT be eligible if...** - You have previously received an HPV vaccine or plan to receive one during the study - You have a history of HPV infection, cervical cancer, abnormal pap smears, or hysterectomy - You have had pelvic radiation - You are pregnant, breastfeeding, or planning a pregnancy within 7 months - You have a fever on the day of enrollment Talk to your doctor to see if this trial is right for you.